Press release
CytomX Therapeutics Presents Preclinical Profile of EpCAM-directed Antibody Drug Conjugate CX-2051 at 2023 World ADC Conference
- CX-2051 is tailored for treatment of EpCAM-expressing cancers by matching target expression and tumor sensitivity with a topoisomerase-1 inhibitor payload -
About this update from Cytomx Therapeutics, Inc.
[{"type":"text","content":"- CX-2051 is tailored for treatment of EpCAM-expressing cancers by matching target expression and tumor sensitivity with a topoisomerase-1 inhibitor payload - - Preclinical data demonstrate a favorable predicted therapeutic index and efficacy across multiple EpCAM-expressing tumors, including colorectal cancer (CRC) - - CX-2051 IND filing expected by year-end 2023 - SOUTH SAN FRANCISCO, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that the Company presented data characterizing the preclinical profile of its EpCAM-targeting ADC, CX-2051, at the World ADC conference taking place October 16-19, 2023, in San Diego, CA. “CX-2051 is designed to address the unmet needs of patients with EpCAM-expressing tumors, including colorectal cancer, where EpCAM expression is uniformly high. EpCAM is a broadly expressed, validated anti-cancer target that to date has been limited in its development potential due to systemic, on-target off-tumor dose-limiting toxicities”, said Marcia P. Belvin, Ph.D., senior vice president and chief scientific officer at CytomX. Continued Dr. Belvin, “Based on our experience with the Probody® Platform and our clinical experience with Probody-ADCs, we have designed CX-2051 to mask target binding in normal tissues and include a next-generation topoisomerase-1 inhibitor payload. We are encouraged by the compelling preclinical profile of CX-2051 and anticipate filing an IND for the program by the end of the year. We aim to launch Phase 1 dose escalation for CX-2051 in solid tumors in 2024, with an initial focus in metastatic colorectal cancer as a priority indication.” Details for the presentation are as follows:Presentation Title: Leveraging Conditional Activation to Localize Antibody Drug Conjugates to the Tumor “Clinical Lessons” TrackSession Date and Time: October 18, 2023, 12:30 pm PST The full presentation is available at the following link: Leveraging Conditional Activation to Localize Antibody Drug Conjugates to the TumorMarcia P. Belvin, Ph.D., Senior Vice President, Chief Scientific Officer, CytomX Therapeutics About CytomX TherapeuticsCytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics localized to the tum...